Lung Transplant HCV, Pilot Study
Key facts
- Who runs it
- University Health Network, Toronto
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Early phase 1
- People taking part
- 26 people enrolled
- Started
- 19 Sept 2017
- Expected to end
- 31 May 2027
- Type of study
- Interventional
- Treatments tested
- Sofosbuvir-velpatasvir (400 mg/100 mg)
- Ex Vivo Lung Perfusion (EVLP)
- Record updated
- 11 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Recipients listed for single or bilateral lung transplant
- HCV Nucleic Acid Amplification Testing (NAT) negative
- Ability to provide written informed consent
Who cannot take part
- Participation in another interventional clinical trial
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
In this study HCV negative recipients will be transplanted with HCV positive lungs. Investigators will attempt to decrease infectivity rates by performing Normothermic Ex vivo Lung Perfusion (EVLP), which is an approved method of donor lung preservation, assessment and treatment, and could be an excellent platform to reduce/eliminate hepatitis C virus. Patients will be treated by the standard approved direct-acting antivirals (DAAs) if infection occurs. It is planned to enroll 20 patients from the Lung transplant wait list in this study. Patients will be actively followed for 6 months including HCV PCR tests and then for up for 5 years to look for evidence of HCV infection and any liver or extra-hepatic complications, as well as standard post-transplant complications. This will be a single center pilot study.
The group in the trial
- HCV+ lung transplant to HCV- recipientsTreatment being tested
HCV+ donor lungs will be treated with Normothermic Ex Vivo Lung Perfusion (EVLP) in order to reduce viral load and minimize risk of HCV transmission. Patients who become viremic defined as at least two consecutive positive samples will receive sofosbuvir/velpatasvir 400 mg/100 mg (Epclusa) for 12 weeks.
Treatment: Sofosbuvir-velpatasvir (400 mg/100 mg) and Ex Vivo Lung Perfusion (EVLP)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Lung Transplantation Using Hepatitis C Positive Donors to Hepatitis C Negative Recipients: A Pilot Study
- Publications
- Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial.The Lancet. Respiratory medicine, 2020
- Record updated
- 11 May 2026